Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 3/20 | 0.55 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.55 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 11/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 4/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.37 |
| ▸ | PDE4A | P27815 | 3/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.36 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.35 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL750088 | 0.85 | PDK2 (0.55) | PDK2PDK4ATAD2PGRPDE3B | |
| SCHEMBL4842759 | 0.77 | PKLR (0.32) | — | |
| SCHEMBL2330085 | 0.73 | — | — | |
| SCHEMBL4003292 | 0.73 | RARB (0.42) | PDK2PGR | |
| SCHEMBL319934 | 0.71 | PDK2 (1.00) | PDK2PDK4PGRPDK1PDK3 | |
| SCHEMBL3072321 | 0.70 | KDM4E (0.33) | PDK2PDK4 | |
| SCHEMBL1450407 | 0.69 | KDM4E (0.44) | PDE3BPDE3A | |
| SCHEMBL22686127 | 0.67 | MARK3 (0.37) | PDK2PDK4PGRPDE3BPDE3A | |
| SCHEMBL7433946 | 0.67 | PDK2 (0.57) | PDK2PDK4ATAD2PGRPDE3B | |
| SCHEMBL2407290 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150126517-A1 | ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF | APOLLO ADMINISTRATIVE AGENCY LLC, AS SUCCESSOR AGENT | 2015-05-07 | — | — | US | claimed |
| EP-2429295-B1 | ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF | ALBANY MOLECULAR RES INC (US) | 2013-12-25 | — | — | EP | claimed |
| US-20130237520-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | GILEAD CONNECTICUT, INC. (US) | 2013-09-12 | — | — | US | claimed |
| EP-2429295-A1 | ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF | Albany Molecular Research, Inc. (US) | 2012-03-21 | — | — | EP | claimed |
| EP-2373169-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Gilead Connecticut, Inc. (US) | 2011-10-12 | — | — | EP | claimed |
| WO-2010132437-A1 | ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-11-18 | — | — | WO | claimed |
| US-20100292242-A1 | ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-11-18 | — | — | US | claimed |
| US-20100222323-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2010-09-02 | — | — | US | claimed |
| WO-2010068257-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | WO | claimed |
| EP-1764358-A2 | Cyclic amides as vanilloid receptor ligands and their use in treatments of inflammatory and neuropathic pain | Amgen, Inc (US) | 2007-03-21 | — | — | EP | claimed |
| US-20060030618-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2006-02-09 | — | — | US | claimed |
| US-20050272931-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-12-08 | — | — | US | claimed |
| EP-1463714-A4 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC (US) | 2005-10-19 | — | — | EP | claimed |
| US-20050227986-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2005-10-13 | — | — | US | claimed |
| EP-1463714-A2 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | Amgen Inc. (US) | 2004-10-06 | — | — | EP | claimed |
| US-20030195201-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2003-10-16 | — | — | US | claimed |
| WO-2003049702-A2 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2003-06-19 | — | — | WO | claimed |
| US-20180086769-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | Kronos Bio, Inc. | 2018-03-29 | — | — | US | disclosed |
| US-20030195201-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. | 2003-10-16 | — | — | US | disclosed |
| WO-2003049702-A2 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272931-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | PDK2 3751/4885PDK4 3526/4885ATAD2 2848/4885 |
| US-20060030618-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | PDK2 3751/4885PDK4 3526/4885ATAD2 2848/4885 |
| US-20030195201-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | PDK2 3969/4885PDK4 3702/4885ATAD2 3157/4885 |
| US-20130237520-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | PDK2 1667/4885PDK4 2899/4885ATAD2 3164/4885 |
| US-20100292242-A1 | ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF | NLN, HTR3B, HTR2C | PDK2 736/4885PDK4 587/4885ATAD2 990/4885 |
| US-20050227986-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | PDK2 3751/4885PDK4 3526/4885ATAD2 2848/4885 |
| US-20150126517-A1 | ARYL, HETEROARYL, AND HETEROCYCLE SUBSTITUTED TETRAHYDROISOQUINOLINES AND USE THEREOF | NLN, HTR3B, HTR2C | PDK2 736/4885PDK4 587/4885ATAD2 990/4885 |
| US-20180086769-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | PDK2 1667/4885PDK4 2899/4885ATAD2 3164/4885 |
| US-20100222323-A1 | IMIDAZOPYRAZINE SYK INHIBITORS | SYK, BTK, ZAP70 | PDK2 1667/4885PDK4 2899/4885ATAD2 3164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.